It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sequencing of B-cell and T-cell immune receptor repertoires helps us to understand the adaptive immune response, although it only provides information about the clonotypes (lineages) and their frequencies and not about, for example, their affinity or antigen (Ag) specificity. To further characterize the identified clones, usually with special attention to the particularly abundant ones (dominant), additional time-consuming or expensive experiments are generally required. Here, we present an extension of a multiscale model of the germinal center (GC) that we previously developed to gain more insight in B-cell repertoires. We compare the extent that these simulated repertoires deviate from experimental repertoires established from single GCs, blood, or tissue. Our simulations show that there is a limited correlation between clonal abundance and affinity and that there is large affinity variability among same-ancestor (same-clone) subclones. Our simulations suggest that low-abundance clones and subclones, might also be of interest since they may have high affinity for the Ag. We show that the fraction of plasma cells (PCs) with high B-cell receptor (BcR) mRNA content in the GC does not significantly affect the number of dominant clones derived from single GCs by sequencing BcR mRNAs. Results from these simulations guide data interpretation and the design of follow-up experiments.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Amsterdam UMC location University of Amsterdam, Epidemiology and Data Science, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Amsterdam Public Health, Methodology, Amsterdam, The Netherlands (GRID:grid.509540.d); Amsterdam Infection and Immunity, Inflammatory Diseases, Amsterdam, The Netherlands (GRID:grid.509540.d)
2 Cancer Center Amsterdam, Amsterdam, The Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X); Amsterdam UMC location University of Amsterdam, Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
3 IBM Research Zurich, Rüschlikon, Switzerland (GRID:grid.410387.9); ETH Zurich, Department of Biosystems Science and Engineering, Basel, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
4 Amsterdam UMC location University of Amsterdam, Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Amsterdam Infection and Immunity, Infectious Diseases, Amsterdam, The Netherlands (GRID:grid.509540.d)
5 Amsterdam UMC location University of Amsterdam, Experimental Immunology, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X)
6 IBM Research Zurich, Rüschlikon, Switzerland (GRID:grid.410387.9)
7 Helmholtz Centre for Infection Research, Department for Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Braunschweig, Germany (GRID:grid.7490.a) (ISNI:0000 0001 2238 295X); Technische Universität Braunschweig, Institute for Biochemistry, Biotechnology and Bioinformatics, Braunschweig, Germany (GRID:grid.6738.a) (ISNI:0000 0001 1090 0254)
8 Cancer Center Amsterdam, Amsterdam, The Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X); Amsterdam UMC location University of Amsterdam, Pathology, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
9 University of Amsterdam, Biosystems Data Analysis, Swammerdam Institute for Life Sciences, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
10 Amsterdam UMC location University of Amsterdam, Epidemiology and Data Science, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Amsterdam Public Health, Methodology, Amsterdam, The Netherlands (GRID:grid.509540.d); Amsterdam Infection and Immunity, Inflammatory Diseases, Amsterdam, The Netherlands (GRID:grid.509540.d); University of Amsterdam, Biosystems Data Analysis, Swammerdam Institute for Life Sciences, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)